BG105794A - (1-фенаци-3-фенил-3-пиперидилетил)пиперидинови производни, метод за тяхното получаване и фармацевтични състави, които ги съдържат - Google Patents

(1-фенаци-3-фенил-3-пиперидилетил)пиперидинови производни, метод за тяхното получаване и фармацевтични състави, които ги съдържат

Info

Publication number
BG105794A
BG105794A BG105794A BG10579401A BG105794A BG 105794 A BG105794 A BG 105794A BG 105794 A BG105794 A BG 105794A BG 10579401 A BG10579401 A BG 10579401A BG 105794 A BG105794 A BG 105794A
Authority
BG
Bulgaria
Prior art keywords
production
pharmaceutical compositions
phenacy
piperidylethyl
phenyl
Prior art date
Application number
BG105794A
Other languages
English (en)
Other versions
BG65031B1 (bg
Inventor
Jean Ducoux
Xavier Emonds-Alt
Patrick Gueule
Vincenzo Proietto
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9901593A external-priority patent/FR2789389B3/fr
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of BG105794A publication Critical patent/BG105794A/bg
Publication of BG65031B1 publication Critical patent/BG65031B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретението се отнася до съединения с формула идо техни соли, солвати и/или хидрати, които проявяват високи афинитет и селективност по отношение на човешки NK1 рецептори на веществото Р. Изобретението се отнася и до метод за получаването им, до междинни съединения с формула VII, посочена в описанието, които са полезни за тяхното получаване, до фармацевтични състави, съдържащи тези съединения,идо използването им за получаване на лекарствени средства за лечение на всички патологии, включващи веществото Р и NK1 човешки рецептори.
BG105794A 1999-02-10 2001-08-08 Пиперидинови производни, метод за тяхното получаване и фармацевтични състави, които ги съдържат BG65031B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9901593A FR2789389B3 (fr) 1999-02-10 1999-02-10 Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
FR9904429A FR2789390B3 (fr) 1999-02-10 1999-04-07 Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
PCT/FR2000/000284 WO2000047572A1 (fr) 1999-02-10 2000-02-08 Derives de (1-phenacy-3-phenyl-3-piperidylethyl)piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
BG105794A true BG105794A (bg) 2002-05-31
BG65031B1 BG65031B1 (bg) 2006-12-29

Family

ID=26234812

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105794A BG65031B1 (bg) 1999-02-10 2001-08-08 Пиперидинови производни, метод за тяхното получаване и фармацевтични състави, които ги съдържат

Country Status (37)

Country Link
US (2) US6642233B1 (bg)
EP (1) EP1150970B1 (bg)
JP (1) JP4648544B2 (bg)
KR (1) KR100611261B1 (bg)
CN (1) CN1273463C (bg)
AR (1) AR028813A1 (bg)
AT (1) ATE370942T1 (bg)
AU (1) AU763716B2 (bg)
BG (1) BG65031B1 (bg)
BR (1) BR0008067A (bg)
CA (1) CA2360894C (bg)
CO (1) CO4980896A1 (bg)
CZ (1) CZ300765B6 (bg)
DE (1) DE60036081T2 (bg)
DK (1) DK1150970T3 (bg)
EE (1) EE04437B1 (bg)
ES (1) ES2291187T3 (bg)
FR (1) FR2789390B3 (bg)
HK (1) HK1038927A1 (bg)
HR (1) HRP20010566A2 (bg)
HU (1) HUP0201281A3 (bg)
ID (1) ID29219A (bg)
IL (2) IL144363A0 (bg)
ME (1) MEP11908A (bg)
NO (2) NO321149B1 (bg)
NZ (1) NZ513053A (bg)
PE (1) PE20001463A1 (bg)
PL (1) PL198561B1 (bg)
PT (1) PT1150970E (bg)
RS (1) RS50210B (bg)
RU (1) RU2220956C2 (bg)
SI (1) SI1150970T1 (bg)
SK (1) SK286401B6 (bg)
TR (1) TR200102331T2 (bg)
TW (1) TWI254712B (bg)
UA (1) UA70986C2 (bg)
WO (1) WO2000047572A1 (bg)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070745A2 (en) * 2002-02-20 2003-08-28 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids
US20050009798A1 (en) 2002-02-20 2005-01-13 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
MXPA06008648A (es) * 2004-01-30 2006-09-04 Pfizer Prod Inc Composiciones farmaceuticas de antagonistas del receptor de neuroquinina y ciclodextrina y metodos para una tolerancia mejorada en el sitio de inyeccion.
FR2873373B1 (fr) * 2004-07-23 2006-09-08 Sanofi Synthelabo Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique
GB2452696B (en) * 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
DE102008015425A1 (de) * 2008-03-20 2010-01-21 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen zur Verringerung von Juckreiz und anderen dermatologischen Missempfindungen, die insbesondere bei Altershaut auftreten können, mit einem Gehalt an (1R,2S,5R)-2-Isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl-cyclohexancarboxamid und/oder (1R,2S,5R)-N-(4-(Cyanomethyl)-phenyl)-2-isopropyl-5-methylcyclohexancarboxamid
DE102008015428A1 (de) * 2008-03-20 2009-09-24 Beiersdorf Ag Kühlende Zubereitungen für den humanen Haut- und/oder Schleimhautkontakt mit einem Gehalt an (1R,2S,5R)-2-Isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl-cyclohexancarboxamid und/oder (1R,2S,5R)-N-(4-(Cyanomethyl)-phenyl)-2-isopropyl-5-methylcyclohexancarboxamid
DE102008015426A1 (de) * 2008-03-20 2009-09-24 Beiersdorf Ag Kühlende kosmetische oder dermatologische Zubereitungen mit einem Gehalt an (1R,2S,5R)-2-Isopropyl-5-methyl-N-(2-(pyridyn-2-yl)ethyl-cyclohexancarboxamid und/oder (1R,2S,5R)-N-(4-(Cyanomethyl)-phenyl)-2-isopropyl-5-methylcyclohexancarboxamid zu Reduktion von Hautrötungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US512901A (en) * 1894-01-16 Folding bed
GB821012A (en) * 1957-01-15 1959-09-30 Rhone Poulenc Sa New phenthiazine derivatives and processes for their preparation
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
EP0777666B1 (en) 1994-08-25 1999-03-03 Merrell Pharmaceuticals Inc. Substituted piperidines useful for the treatment of allergic diseases
CA2162786A1 (en) 1994-11-22 1996-05-23 Philip Arthur Hipskind Heterocyclic tachykinin receptor antagonists

Also Published As

Publication number Publication date
HUP0201281A3 (en) 2003-05-28
AU2553100A (en) 2000-08-29
BG65031B1 (bg) 2006-12-29
TWI254712B (en) 2006-05-11
EE04437B1 (et) 2005-02-15
EP1150970B1 (fr) 2007-08-22
CA2360894A1 (en) 2000-08-17
US6642233B1 (en) 2003-11-04
PL350243A1 (en) 2002-12-02
CA2360894C (en) 2009-09-22
JP2002536442A (ja) 2002-10-29
RU2220956C2 (ru) 2004-01-10
EE200100417A (et) 2002-12-16
UA70986C2 (uk) 2004-11-15
PE20001463A1 (es) 2001-02-21
SK11392001A3 (sk) 2002-02-05
DK1150970T3 (da) 2007-12-17
AR028813A1 (es) 2003-05-28
CN1345317A (zh) 2002-04-17
US20040072840A1 (en) 2004-04-15
ID29219A (id) 2001-08-16
MEP11908A (en) 2010-06-10
KR20010101818A (ko) 2001-11-14
CN1273463C (zh) 2006-09-06
CO4980896A1 (es) 2000-11-27
ES2291187T3 (es) 2008-03-01
DE60036081T2 (de) 2008-05-15
NO20013878D0 (no) 2001-08-08
BR0008067A (pt) 2001-11-06
YU56401A (sh) 2004-03-12
JP4648544B2 (ja) 2011-03-09
KR100611261B1 (ko) 2006-08-10
RS50210B (sr) 2009-07-15
FR2789390B3 (fr) 2001-03-09
SI1150970T1 (sl) 2008-02-29
HRP20010566A2 (en) 2002-08-31
US6951940B2 (en) 2005-10-04
PL198561B1 (pl) 2008-06-30
TR200102331T2 (tr) 2002-03-21
WO2000047572A1 (fr) 2000-08-17
EP1150970A1 (fr) 2001-11-07
CZ300765B6 (cs) 2009-08-05
NO20051958L (no) 2001-10-10
ATE370942T1 (de) 2007-09-15
NO321149B1 (no) 2006-03-27
NO20013878L (no) 2001-10-10
IL144363A0 (en) 2002-05-23
HUP0201281A2 (en) 2002-09-28
NZ513053A (en) 2002-10-25
AU763716B2 (en) 2003-07-31
FR2789390A1 (fr) 2000-08-11
IL180579A0 (en) 2007-06-03
CZ20012888A3 (cs) 2001-11-14
HK1038927A1 (en) 2002-04-04
PT1150970E (pt) 2007-11-07
SK286401B6 (sk) 2008-09-05
DE60036081D1 (de) 2007-10-04

Similar Documents

Publication Publication Date Title
RS20050394A (en) Novel aromatic fluoroglycoside derivatives, pharmaceutical products containing said compounds and the use thereof
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
IS6451A (is) Nýjar 1,3-díhýdró-2H-indól-2-ón afleiður, framleiðsluaðferð og lyfjasamsetningar sem innihalda þær
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
DK0380063T3 (da) 1,2-Cyclohexylaminoarylamider til anvendelse som analgetika
GB9914486D0 (en) Medicaments
TNSN05160A1 (en) Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof
IL150201A0 (en) Novel piperidine and piperazine derivatives
EP0896533A4 (en) PENTAFLUOROBENZEN SULPHONAMIDES AND ANALOGS
HUT68963A (en) Novel 4-arylpiperazines and 4-arylpiperidines, pharmaceutical compositions comprising them and the proces for producing thereof
SE9904505D0 (sv) Novel compounds
MY125749A (en) Aralkyl and aralkylidene heterocyclic lactams and imides
MXPA02009643A (es) Sintesis acortada de derivados de 3,3-diarilpropilamina.
MX9708696A (es) Cefalosporinas antibacterianas.
AU1549500A (en) Use of n-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis
MX9804106A (es) Sales de derivados de quinolina como antagonistas de nk3.
BG105794A (bg) (1-фенаци-3-фенил-3-пиперидилетил)пиперидинови производни, метод за тяхното получаване и фармацевтични състави, които ги съдържат
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
HU9800970D0 (en) Process for producing pharmaceutical compositions containing heptapeptide somatostatin derivatives of neurogene- and non-neurogene-antiflogistic and analgesic activity and peptidomimetica
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
MD522G2 (ro) Noi derivaţi de piperidinii tioindol, procedeu de preparare a lor, compoziţii farmaceutice care le conţin, utilizare a lor ca analgezice
BG105923A (bg) Нови морфолинови производни, метод за тяхното получаване и фармацевтични състави, които ги съдържат
NZ332545A (bg)
YU86603A (sh) Novi derivati piperidinkarboksamida, postupak za njihovo pripremanje i farmaceutske kompozicije koje ih sadrže